Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: Toward a standard of care

Inflammatory Bowel Diseases

Volumn 14, Issue 1, 2008, Pages 106-113

  Poppers, David M ^a   Scherl, Ellen J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Infection; Inflammatory bowel disease; Pneumonocystis; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ATOVAQUONE; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; ETANERCEPT; FANSIDAR; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; MALOPRIM; MERCAPTOPURINE; METHOTREXATE; PENTAMIDINE; PREDNISONE; PYRAZINAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; SULFAMETHOXAZOLE; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; ENTERITIS; GASTROENTEROLOGY; HEALTH CARE; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; ORGAN TRANSPLANTATION; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PNEUMONIA, PNEUMOCYSTIS;

EID: 38849127538     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20261     Document Type: Review

References (60)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204-211.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;1371-1385.
3. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
4. Maser E, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as salvage therapies for each other in steroid refractory ulcerative colitis. Gastroenterology. 2007;132:4(suppl 2)S1132, A180.
5. [No authors provided]. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Recomm Rep. 1992;41:1-11.
6. Asch SM, Gifford AL, Bozzette SA, et al. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States. J Acquir Immune Defic Syndr. 2001;28:340-344.
7. Cvetkoviě RS, Wellington K. Valganciclovir - a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65:859-878.
8. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845.
9. Slifkin M, Doron S, Syndman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64:2763-2792.
10. Goh J, Wight D, Parkes M, et al. Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: coprecipitants or coincidence? Am J Gastroenterol. 2002;97:1061-1062.
11. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Int Med. 2005;143:870-881.
12. Schurmann D, Bergmann F, Albrecht H, et al. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with abherent HIV infection. Eur J Clin Microbiol Infect Dis. 2002;21:353-361.
13. Nahimana A, Rabodonirina M, Bille J, et al. Mutations of Pneumocystis jiroveci dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301-4305.
14. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses. 1992-1997. MMWR CDC Surveill Summ. 1999;48:1-22.
15. DiRienzo AG, van Der Horst C, Finkelstein DM, et al. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:89-94.
16. Dworkin MS, Williamson J, Jones JL, et al. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis. 2001;33:393-398.
17. De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36:879-883.
18. Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis. 2003;36:645-651.
19. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17:770-782.
20. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprimsulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122:755-761.
21. 6/L. AIDS. 2001;15:1509-1515.
22. Grimade K, Seingler GH. Cotrimazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database. System Rev 2006; Jan 25; C15:CD003508.
23. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-1224.
24. Bernstein CN, Kolodny M, Block E, et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids. Am J Gastroenterol. 1993;88:574-577.
25. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Therap. 2005;21:307-319.
26. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740-746.
27. Khatchatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1558-1560.
28. Takenaka R, Okada H, Mizuno M, et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J Gastroenterol. 2004;39:1114-1119.
29. Lemaire CM, Browning JC, Hsu S. Medical pearl: Pneumocystis pneumonia prophylaxis for patients on chronic systemic corticosteroids.
30. Hardy AM, Wajszczuk CP, Suffredini AF, et al. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis. 1984;149:143-147.
31. Kountouras J, Zavos C, Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med. 2004;8:317-328.
32. Rafiee P, Johnson CP, Li MS, et al. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem. 2002;277:35605-35615.
33. Van Gossum A, Schmit A, Adler M, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg. 1997;60:197-200.
34. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
35. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med. 1992;327:497-498.
36. Quan VA, Saunders BP, Hicks BH, et al. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ. 1997;314:363-364.
37. Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum. 1997;40:973-976.
38. Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:191-208.
39. Sartor RB, Sandborn WJ. Kirsner's inflammatory bowel diseases. Amsterdam: Elsevier; 2004.
40. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
41. Seddik M, Melliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's Disease. Inflamm Bowel Dis. 2005;11:618-620.
42. Tai TL, O'Rourke KP, McWeeney M, et al. . Rheumatology. 2002;41:951-952.
43. Seddik M, Meliez H, Seuy D, et al. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis. 2004;10:436-437.
44. Minnee RC, Stokkers P, Riemens SC, et al. Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis [in Dutch]. Ned Tijdschr Geneeskd. 2005;149:2290-2295.
45. Mathew BS, Grossman SA. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat Rev. 2003;29:105-119.
46. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis - a therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-660.
47. Kaur N, Mahl TC. Pneumoncystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481-1484.
48. Ward MM, Donald F. Pneumocystic carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780-789.
49. Kaneko Y, Suwa A, Ikeda Y, et al. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Mod Rheumatol. 2006;16:36-38.
50. Mori S, Imamura F, Kiyofuji C, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16:58-62.
51. Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rhuematol. 2006;12:114-117.
52. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8:R66.-
53. Roblin X, Serre-Debeauvais F, Phelip JM, et al. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Phamacol Ther. 2003;18:917-925.
54. Olsen SL, Renlund DG, O'Connell JB, et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993;56:359-362.
55. Marras TK, Sanders K, Lipton JH, et al. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transplant Infect Dis. 2002;4:66-74.
56. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162:921-928.
57. Oshitani N, Matsumoto T, Moriyama Y, et al. Drug-induced pneumonitis caused by sulfamethoxazole trimethoprim during treatment of Pneumocystis carinii pneumonia in a patient with refractory ulcerative colitis. J Gastroenterol. 1998;33:578-581.
58. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1541-1549.
59. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New Engl J Med. 2004;350:876-885.
60. Lichtenstein GR, Abreu MT, Cohen R, et al.1 American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-939.